By combining saxagliptin and metformin, Komboglyze effectively reduces blood glucose levels in adults when diet and exercise alone have not been adequate. This dual mechanism of action makes it a comprehensive choice for managing type 2 diabetes mellitus.
However, Komboglyze is not suitable for patients with type 1 diabetes or the treatment of diabetic ketoacidosis since it would not be effective in these conditions. The treatment should be initiated carefully, considering the potential risk of lactic acidosis induced by metformin.